Physician profile
Stephen J Swartz
NPI 1245211705
$12,618.75
in general payments reported to CMS, 2019-2025
55 companies · $1,730 in 2025
The $1,730 reported for 2025 was more than what 92% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,426 · 2020: $1,819 · 2021: $1,840 · 2022: $1,738 · 2023: $1,919 · 2024: $2,147 · 2025: $1,730.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,788 · Education: $8.45.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,787.64 |
| Education | $8.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,372.53 | 2019-2025 | Breztri, Farxiga, Airsupra |
| Abbvie INC. | $1,250.80 | 2019-2025 | Qulipta, Vraylar, Ubrelvy |
| Novo Nordisk INC | $1,229.54 | 2019-2025 | Ozempic, Rybelsus |
| Glaxosmithkline, LLC. | $1,123.50 | 2019-2025 | Trelegy Ellipta, Arexvy |
| Pfizer INC. | $985.48 | 2019-2025 | |
| Lilly USA, LLC | $895.26 | 2019-2025 | Emgality, Amyvid, Kisunla |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $787.35 | 2019-2025 | Xifaxan |
| Merck Sharp & Dohme LLC | $726.69 | 2019-2025 | Verquvo, Belsomra, Steglatro |
| Janssen Pharmaceuticals, INC | $408.02 | 2019-2024 | Xarelto |
| Amgen INC. | $296.36 | 2019-2025 | Repatha, Otezla, Otezla |
| Abbott Laboratories | $259.34 | 2020-2025 | Freestyle Libre 3 |
| Novartis Pharmaceuticals Corporation | $255.67 | 2019-2024 | |
| Sumitomo Pharma America, INC. | $240.91 | 2023-2025 | Gemtesa |
| Eisai INC. | $238.03 | 2021-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $211.08 | 2023-2025 |
Show all 55 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phathom Pharmaceuticals, INC. | $200.10 | 2024-2025 | Voquezna |
| Kowa Pharmaceuticals America, INC. | $171.09 | 2019-2022 | |
| Biogen, INC. | $155.96 | 2021-2025 | Skyclarys |
| Exact Sciences Corporation | $149.54 | 2023-2025 | Cologuard Collection Kit |
| Allergan, INC. | $140.24 | 2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $138.79 | 2019-2024 | Jardiance |
| Biohaven Pharmaceutical Holding Company LTD. | $136.79 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $112.75 | 2019-2021 | |
| E.R. Squibb & Sons, L.L.C. | $88.86 | 2019-2022 | |
| Genentech USA, INC. | $82.30 | 2019-2022 | |
| Vertex Pharmaceuticals Incorporated | $69.43 | 2025 | |
| Otsuka America Pharmaceutical, INC. | $60.12 | 2023-2024 | Rexulti |
| Dexcom, INC. | $57.95 | 2024 | Dexcom G6 Transmitter |
| Baxter Healthcare | $55.77 | 2025 | Hillrom - Carnation Ambulatory Monitor |
| Insmed, INC. | $52.28 | 2025 | Brinsupri, Arikayce |
| Azurity Pharmaceuticals, INC. | $50.02 | 2024-2025 | Horizant |
| Nevro Corp. | $47.74 | 2024 | Senza |
| Life Molecular Imaging LTD | $47.08 | 2019-2024 | Neuraceq |
| Astellas Pharma US INC | $46.61 | 2020-2023 | Veozah |
| Sunovion Pharmaceuticals INC. | $38.36 | 2020-2022 | |
| Topcon Healthcare Solutions, INC. | $37.06 | 2020 | |
| Verona Pharma, INC. | $36.88 | 2025 | Ohtuvayre |
| Philips North America LLC | $33.82 | 2019-2020 | |
| Lundbeck LLC | $32.91 | 2024 | Vyepti |
| Insightec,INC | $28.77 | 2025 | Exablate |
| Takeda Pharmaceuticals U.S.A., INC. | $28.58 | 2019 | |
| Esperion Therapeutics, INC. | $28.16 | 2021-2025 | Nexletol |
| Sanofi-Aventis U.S. LLC | $24.26 | 2020-2021 | |
| Edwards Lifesciences Corporation | $20.62 | 2023 | Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Boston Scientific Corporation | $19.95 | 2024 | Watchman Flx |
| Amphastar Pharmaceuticals, INC. | $17.45 | 2024 | |
| Aimmune Therapeutics, INC. | $17.25 | 2024 | |
| Sanofi Pasteur INC. | $14.93 | 2019 | |
| Medicure Pharma INC. | $14.60 | 2021 | |
| Alexion Pharmaceuticals, INC. | $14.47 | 2020 | |
| Biohaven Pharmaceuticals, INC. | $13.52 | 2021 | |
| Cashflow Solutions, LLC | $13.51 | 2025 | Lympha Press Optimal Plus(US) Bt, Pcd-51 731a (US) - White, Pcd-52 737a (US) White |
| Ibsa Pharma INC. | $13.50 | 2025 | Tirosint, Licart, Flector |
| Nestle Healthcare Nutrition INC. | $13.25 | 2023 | |
| Amarin Pharma, INC. | $12.92 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephen Swartz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.